SCHEMBL4744894

SCHEMBL4744894

Cc1cc(C)cc(-c2cc(Cl)c3nonc3c2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
GAA P10253 2/20 0.37
APAF1 O14727 2/20 0.37
THRB P10828 2/20 0.37
RECQL P46063 2/20 0.37
BLM P54132 2/20 0.37
SAE1 Q9UBE0 2/20 0.37
UBA2 Q9UBT2 2/20 0.37
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37
GALK1 P51570 1/20 0.37
CASP6 P55212 1/20 0.37
LMNA P02545 3/20 0.34
ALDH1A1 P00352 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
NPC1 O15118 2/20 0.33
HTT P42858 2/20 0.33
RAB9A P51151 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743550 0.85 AKR1C2 (0.43) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL14446368 0.85 MAPT (0.41) MAPTL3MBTL1GAAAPAF1THRB
SCHEMBL5242800 0.80 LMNA (0.35) MAPTL3MBTL1GAATHRBLMNA
SCHEMBL4746064 0.79 EPAS1 (0.37) MAPTL3MBTL1GAAAPAF1THRB
SCHEMBL4745394 0.72 ADORA2A (0.44) MAPTALDH1A1KMT2ANPC1RAB9A
SCHEMBL4744895 0.72 GRIN2B (0.39) MAPTL3MBTL1GAALMNAALDH1A1
SCHEMBL4744881 0.72 KIF11 (0.41) CASP3
SCHEMBL15571232 0.69 MAPT (0.37) MAPTL3MBTL1GAAAPAF1THRB
SCHEMBL4786410 0.69 CASP3 (0.43) MAPTL3MBTL1THRBALDH1A1MEN1
SCHEMBL4746821 0.69 ALDH1A1 (0.43) L3MBTL1LMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP MAPT 1681/4885L3MBTL1 2603/4885GAA 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.